Abstract:Abstract Chondrosarcoma, a highly resilient cancer characterized by limited effective treatment options, represents a significant therapeutic challenge. bAP15, a novel inhibitor of deubiquitylating enzymes (DUBs), has emerged as a promising therapeutic agent, exhibiting anti-tumor activity in various cancer models. This study investigated the efficacy of bAP15 against chondrosarcoma in vitro and in vivo. To evaluate bAP15's effects on chondrosarcoma cells, the SW1353 and JJ012 cell lines were employed. Cell viability, apoptosis, and cell cycle progression were assessed using MTT assay and flow cytometry. Western blotting was utilized to analyze apoptosis, cell stress, and endoplasmic reticulum (ER) stress. Additionally, a xenograft mouse model was established to examine the in vivo anti-tumor potential of bAP15. Compared to normal cartilage tissue, chondrosarcoma cells exhibited significantly higher expression of the DUB UCHL5, suggesting its potential involvement in chondrosarcoma development. Treatment with bAP15 effectively induced apoptosis in chondrosarcoma cells by activating caspases and cleaving PARP. Furthermore, bAP15 enhanced ER stress by activating caspase-4 and CHOP. In the xenograft mouse model, bAP15 demonstrated remarkable anti-tumor efficacy with minimal toxicity. These findings highlight the potential of bAP15 as a therapeutic strategy for chondrosarcoma. Its ability to induce ER stress and cell cycle arrest, coupled with its in vivo anti-tumor activity, provides compelling evidence for its further development as a novel treatment option for this challenging cancer. Citation Format: Kuan-Lin Kuo, Fu-Shun Hsu, Shang-Jen Chang, Shih-Ming Liao, Wei-Chou Lin, Tzt-Yao Ke, Tzu-Ting Liu, Kuo-Yuan Huang. Investigating bAP15, a new inhibitor of UCHL5/USP14 deubiquitinating enzymes, as a potential treatment for chondrosarcoma: A comprehensive in vivo and in vitro study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4521.

Histone Deacetylase Inhibitors Repress Chondrosarcoma Cell Proliferation.

Antitumor Activity of Histone Deacetylase Inhibitor Trichostatin A in Osteosarcoma Cells

Histone Deacetylase Inhibitors Suppress the Growth of Human Osteosarcomas in Vitro and in Vivo.

Histone Deacetylase Inhibits the Growth and Migration of Human Osteosarcoma Cells

HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia

The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth Via Regulation of YAP/p21/c-Myc Signaling.

Therapeutic Applications of Histone Deacetylase Inhibitors in Sarcoma

Targeting of Histone Deacetylases to Reactivate Tumour Suppressor Genes and Its Therapeutic Potential in a Human Cervical Cancer Xenograft Model

Effects of Histone Deacetylase Inhibitor on Apoptosis of Osteosarcoma MNNG/HOS Cells in Vitro

The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells

PLCD1-Induced DNA Damage Inhibits the Tumor Growth Via Downregulating CDKs in Chondrosarcoma

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation

Constitutive Hedgehog Signaling in Chondrosarcoma Up-Regulates Tumor Cell Proliferation.

Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.

Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling

Histone Deacetylase Inhibitors Trichostatin A and Valproic Acid Induce Cell Cycle Arrest and P21 Expression in Immortalized Human Endometrial Stromal Cells.

Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy

Exploring Adenosine Analogues for Chondrosarcoma Therapy: In Vitro and In Vivo Insights

Abstract 4521: Investigating bAP15, a new inhibitor of UCHL5/USP14 deubiquitinating enzymes, as a potential treatment for chondrosarcoma: A comprehensive in vivo and in vitro study

Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.

Trichostatin A Inhibits Proliferation of Triple Negative Breast Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis.